COAG

38.8652.50%
CE

Catherine Eilleen Madigan

Chief Medical Officer

Dr. Catherine Eilleen Madigan, M.D., also known as Kate, is Chief Medical Officer of Hemab ApS from January 2025. Dr. Madigan served as Chief Medical Officer of Syndax Pharmaceuticals, Inc. since March 01, 2022 until December 20, 2024. She has been the Chief Medical Officer at Hemab Therapeutics Holdings, Inc. since January 2025. She served as Vice President, Head of Clinical Development at Syros Pharmaceuticals, Inc., from June 2019 to February 2022. Prior to joining Syros, she served as Senior Medical Director at Alnylam Pharmaceuticals and was a Medical Director in Biogen's Rare Disease Innovation Unit. Before moving into industry, she held various academic positions of increasing responsibility at University of California San Diego/ Rady Children's Hospital San Diego. She received a B.A. in Asian Studies from Dartmouth College and an M.D. from the Keck School of Medicine of the University of Southern California.

Positions